<DOC>
	<DOC>NCT00959582</DOC>
	<brief_summary>This study will characterize FDG-PET (18F-Fluorodeoxyglucose-Positron Emission Tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based therapy.</brief_summary>
	<brief_title>Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Patient has ovarian, primary peritoneal, or fallopian tube cancer Patient has first or subsequent relapse Patient has had at least on prior platinumbased treatment for ovarian cancer Patient is scheduled to receive treatment with carboplatin or cisplatin monotherapy or combination where one of the drugs is a platinum Patient is not pregnant Patient has had abdominal surgery within the last 6 weeks Patient has life expectancy &lt; 6 months Patient has had radiotherapy to the abdomen or pelvis within the last 6 months Patient has poorly controlled diabetes</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Relapsed ovarian cancer</keyword>
</DOC>